A detailed history of Versant Capital Management, Inc transactions in Exelixis, Inc. stock. As of the latest transaction made, Versant Capital Management, Inc holds 238 shares of EXEL stock, worth $8,341. This represents 0.0% of its overall portfolio holdings.

Number of Shares
238
Previous 238 -0.0%
Holding current value
$8,341
Previous $5,000 20.0%
% of portfolio
0.0%
Previous 0.0%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Jul 05, 2024

BUY
$20.34 - $23.73 $4,678 - $5,457
230 Added 2875.0%
238 $5,000
Q3 2023

Oct 11, 2023

SELL
$19.04 - $22.74 $571 - $682
-30 Reduced 78.95%
8 $0
Q2 2023

Jul 10, 2023

BUY
$18.17 - $20.48 $690 - $778
38 New
38 $0
Q3 2021

Oct 29, 2021

SELL
$16.3 - $21.14 $994 - $1,289
-61 Closed
0 $0
Q2 2021

Jul 22, 2021

BUY
$17.95 - $25.56 $1,094 - $1,559
61 New
61 $1,000

Others Institutions Holding EXEL

About EXELIXIS, INC.


  • Ticker EXEL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 321,832,000
  • Market Cap $11.3B
  • Description
  • Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...
More about EXEL
Track This Portfolio

Track Versant Capital Management, Inc Portfolio

Follow Versant Capital Management, Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Versant Capital Management, Inc, based on Form 13F filings with the SEC.

News

Stay updated on Versant Capital Management, Inc with notifications on news.